Skip to Main Content

Elizabeth Holmes was poised to become the next college-dropout-turned-tech-billionaire. But there was only one problem: Her technology didn’t work.

Holmes, the founder of the blood-testing company Theranos, will now finally stand trial for allegedly defrauding doctors, patients, and investors. She and her business partner and ex-boyfriend, Ramesh “Sunny” Balwani, were indicted by a federal grand jury in June 2018. The trial was originally scheduled for summer 2020, but was postponed multiple times because of the coronavirus pandemic and Holmes’ pregnancy.

advertisement

Holmes rose to prominence in the mid-2010s after promising revolutionary machines that could run multiple cheap, quick diagnostic tests with just a single drop of blood. At its peak, Theranos was valued at a stunning $9 billion. But serious doubts about the company swelled after the Wall Street Journal published a series of stories detailing problems with the company’s technology. Theranos was investigated by multiple federal agencies, and by September 2018, it announced that it was shutting down.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.